Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS.

Clin Cancer Res. 2012 Sep 1;18(17):4820-9. doi: 10.1158/1078-0432.CCR-12-0098. Epub 2012 Jul 5.

2.

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.

Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS.

Clin Cancer Res. 2014 Dec 1;20(23):5918-26. doi: 10.1158/1078-0432.CCR-14-1143. Epub 2014 Sep 26.

3.

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.

Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL.

BJU Int. 2015 Oct;116(4):546-55. doi: 10.1111/bju.12986. Epub 2015 Jun 8.

PMID:
25407442
4.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA.

J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26.

5.

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.

Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. doi: 10.1007/s00280-014-2389-9. Epub 2014 Jan 23.

PMID:
24452395
6.

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.

Diaz LA Jr, Coughlin CM, Weil SC, Fishel J, Gounder MM, Lawrence S, Azad N, O'Shannessy DJ, Grasso L, Wustner J, Ebel W, Carvajal RD.

Clin Cancer Res. 2015 Mar 15;21(6):1281-8. doi: 10.1158/1078-0432.CCR-14-1829. Epub 2014 Nov 14.

8.

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R.

Clin Cancer Res. 2014 Apr 15;20(8):2192-204. doi: 10.1158/1078-0432.CCR-13-2200. Epub 2014 Feb 21.

9.

Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.

Doi T, Ohtsu A, Tahara M, Tamura T, Shirao K, Yamada Y, Otani S, Yang BB, Ohkura M, Ohtsu T.

Int J Clin Oncol. 2009 Aug;14(4):307-14. doi: 10.1007/s10147-008-0855-2. Epub 2009 Aug 25.

PMID:
19705240
10.

Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.

LoRusso P, Jänne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, Ang A, Halim AB, Beckman RA, Beaupre D, Berlin J.

Clin Cancer Res. 2013 Jun 1;19(11):3078-87. doi: 10.1158/1078-0432.CCR-12-3051. Epub 2013 Apr 16.

11.

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.

Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ.

Ann Oncol. 2015 Jun;26(6):1230-7. doi: 10.1093/annonc/mdv144. Epub 2015 Mar 18.

12.

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L.

Clin Cancer Res. 2010 Jan 15;16(2):699-710. doi: 10.1158/1078-0432.CCR-09-1365. Epub 2010 Jan 12.

13.

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J.

Clin Cancer Res. 2007 Oct 15;13(20):6187-94.

14.

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.

Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, Zugmaier G, Verweij J, de Bono JS, de Jonge M.

Br J Cancer. 2007 Nov 19;97(10):1338-43. Epub 2007 Nov 13.

15.

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O'Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW.

Cancer Chemother Pharmacol. 2009 May;63(6):1065-71. doi: 10.1007/s00280-008-0811-x. Epub 2008 Sep 16.

PMID:
18795291
16.

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.

Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM.

Clin Cancer Res. 2010 Jul 1;16(13):3485-94. doi: 10.1158/1078-0432.CCR-10-0505. Epub 2010 May 17.

17.

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP, Lee NY, Hurwitz HI, Nixon AB.

Cancer Med. 2014 Jun;3(3):580-91. doi: 10.1002/cam4.207. Epub 2014 Feb 14.

18.

Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.

Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA.

Clin Cancer Res. 2008 Jan 15;14(2):502-8. doi: 10.1158/1078-0432.CCR-07-1509.

19.

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS.

J Clin Oncol. 2009 Jul 20;27(21):3557-65. doi: 10.1200/JCO.2008.19.6683. Epub 2009 Jun 22.

20.

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.

Rosen PJ, Sweeney CJ, Park DJ, Beaupre DM, Deng H, Leitch IM, Shubhakar P, Zhu M, Oliner KS, Anderson A, Yee LK.

Clin Cancer Res. 2010 May 1;16(9):2677-87. doi: 10.1158/1078-0432.CCR-09-2862. Epub 2010 Apr 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk